{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:28:06Z","timestamp":1788485286897,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The role of serum Procalcitonin (PCT) in adults in diagnosis of Community acquired pneumonia (CAP) is well established, however, role in pediatric CAP remains controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The objective of this study was to investigate the utility of serum procalcitonin in differentiating bacterial community-acquired lower respiratory tract infection from non-bacterial respiratory infection in children; radiologically confirmed pneumonia was used as the reference. In addition, we assessed the utility of adding the PCT assay to the clinical criteria for diagnosis of pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study design<\/jats:title>\n                <jats:p>Subanalysis of a larger prospective,multicentriccohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Participants<\/jats:title>\n                <jats:p>Children, 2\u00a0months to 59\u00a0months of age, attending paediatric OPD of 5 urban tertiary care hospitals, suffering from acute respiratory infection (ARI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Intervention<\/jats:title>\n                <jats:p>Detailed clinical history and examination findings of enrolled children were recorded on predesigned case record form. Samples for PCT were obtained at admission and were measured centrally at the end of the study except for one site using VIDAS\u00ae B.R.A.H.M.S PCT kit (Biomerieux SA, France).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Outcomes<\/jats:title>\n                <jats:p>Sensitivity and specificity of procalcitonin for diagnosis of radiologically confirmed pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum Procalcitonin was measured in 370 patients; median (IQR) age of these children being 12 (7, 22) months, 235 (63.5%) were boys. The median (IQR)\u00a0serum procalcitonin concentration was 0.1(0.05, 0.4) ng\/mL.Sensitivity and specificity of raised PCT (&gt;\u20090.5\u00a0ng\/mL) for pneumonia as per any CXR abnormalities were 29.7% and87.5%,(<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) respectively. Raised PCT was also significantly associated with consolidation (34.5%,79.2%,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.02)and pleural effusion(54.6%,79%,<jats:italic>P<\/jats:italic>\u2009&lt;\u2009001)<jats:bold>.<\/jats:bold> Adding PCT to the existing clinical criteria of WHO did not improve the sensitivity for diagnosis of pneumonia. PCT was significantly higher in children with severe pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Positive PCT (&gt;\u20090.5\u00a0ng\/mL) is significantly associated with radiographic pneumonia but not with pneumonia based on WHO criteria.However, it can act as a surrogate marker for severe pneumonia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03286-2","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:06:07Z","timestamp":1650445567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Role of procalcitonin in diagnosis of community acquired pneumonia in Children"],"prefix":"10.1186","volume":"22","author":[{"given":"Vinod H.","family":"Ratageri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puspha","family":"Panigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi R.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish Prasad","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeed Iqbal","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhadresh","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prawin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarendra","family":"Mahapatro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir Ahmad","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Jat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ijms18020447","volume":"18","author":"Esposito S Principi N","year":"2017","unstructured":"PrincipiN ES. Biomarkers in pediatric community-acquired pneumonia. Int J Mol Sci. 2017;18:447.","journal-title":"Int J Mol Sci"},{"key":"3286_CR2","first-page":"406","volume":"30","author":"JY Lee","year":"2010","unstructured":"Lee JY, Hwang SJ, Shim JW, Jung HL, Park MS, Woo HY, Shim JY. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia. Korean J Lab Med. 2010;30:406\u201313.","journal-title":"Korean J Lab Med."},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jiac.2014.06.003","volume":"10","author":"T Hoshina","year":"2014","unstructured":"Hoshina T, Nanishi E, Kanno S, Nishio H, Kusuhara K, Hara T. The utility of biomarkers in differentiating bacterial from nonbacterial lower respiratory tract infection in hospitalized children: Difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother. 2014;10:616\u201320.","journal-title":"J Infect Chemother"},{"key":"3286_CR4","first-page":"2803","volume":"256","author":"JW Jacobs","year":"1981","unstructured":"Jacobs JW, Lund PK, Potts JT Jr, Bell NH, Habener JF. Procalcitonin is a glycoprotein. J BiolChem. 1981;256:2803\u20137.","journal-title":"J BiolChem"},{"key":"3286_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s001340000624","volume":"26","author":"K Reinhart","year":"2000","unstructured":"Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000;26:1193\u2013200.","journal-title":"Intensive Care Med"},{"key":"3286_CR6","first-page":"4300","volume":"19","author":"F Zhu","year":"2015","unstructured":"Zhu F, Jiang Z, Li WH, Wei HY, SuGD. Clinical significance of serum procalcitonin level monitoring on early diagnosis of severe pneumonia on children. Eur Rev Med Pharmacol Sci. 2015;19:4300\u20133.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"3286_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jpids\/piw091","volume":"7","author":"C Stockmann","year":"2018","unstructured":"Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalizedchildren with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc. 2018;7:46\u201353.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"3286_CR8","first-page":"000","volume":"23","author":"VC Souza-Danta","year":"2017","unstructured":"SalluhJIF, Souza-Danta VC, Po\u00b4vo P. The current status of biomarkers for the diagnosis of nosocomial pneumonias. CurrOpinCrit Care. 2017;23:000\u2013000.","journal-title":"CurrOpinCrit Care"},{"key":"3286_CR9","first-page":"171","volume":"21","author":"P Mahajan","year":"2014","unstructured":"Mahajan P, Grzybowski M, Chen X, Kannikeswaran N, Stanley R, Singal B, et al. Procalcitonin as a marker of serious bacterial infections in febrile children younger than 3 years old. AcadEmerg Med. 2014;21:171\u20139.","journal-title":"AcadEmerg Med"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12013-015-0631-7","volume":"73","author":"F Zhu","year":"2015","unstructured":"Zhu F, Wei H, Li W. Significance of serum procalcitonin levels in differential diagnosis of pediatric pneumonia. Cell BiochemBiophys. 2015;73:619\u201322.","journal-title":"Cell BiochemBiophys"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clinbiochem.2015.09.008","volume":"49","author":"L Agnello","year":"2016","unstructured":"Agnello L, Bellia C, Di Gangi M, Lo Sasso B, Calvaruso L, Bivona G, et al. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children. Clin Biochem. 2016;49:47\u201350.","journal-title":"Clin Biochem"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/00006454-200007000-00003","volume":"19","author":"P Toikka","year":"2000","unstructured":"Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J. 2000;19:598\u2013602.","journal-title":"Pediatr Infect Dis J"},{"key":"3286_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/INF.0b013e31824dacf4","volume":"31","author":"C Luaces-Cubells","year":"2012","unstructured":"Luaces-Cubells C, Mintegi S, Garc\u00eda-Garc\u00eda JJ, Astobiza E, Garrido-Romero R, Velasco-Rodr\u00edguez J, Benito J. Procalcitonin to detect invasive bacterial infection in non-toxic-appearing infants with fever without apparent source in the emergency department. Pediatr Infect Dis J. 2012;31:645\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"3286_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.rmed.2011.09.003","volume":"105","author":"S Esposito","year":"2011","unstructured":"Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105:1939\u201345.","journal-title":"Respir Med"},{"issue":"11","key":"3286_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s13312-021-2369-1","volume":"58","author":"JP Goyal","year":"2021","unstructured":"Goyal JP, Kumar P, Mukherjee A, Das RR, Bhat JI, Ratageri V, Vyas B, Lodha R, Acute Respiratory Infection Treatment Unit Study Group. Risk Factors for the Development of Pneumonia and Severe Pneumonia in Children. Indian Pediatr. 2021;58(11):1036\u20139.","journal-title":"Indian Pediatr."},{"issue":"11","key":"3286_CR16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s13312-021-2367-3","volume":"58","author":"RR Das","year":"2021","unstructured":"Das RR, Satapathy AK, Mukherjee A, Goyal JP, Bhat JI, Ratageri VH, Vyas B, Lodha R, Members of The ATU (Acute Respiratory Infection Treatment Unit) Group. Role of Clinical Criteria and Oxygen Saturation Monitoring in Diagnosis of Childhood Pneumonia in Children Aged 2 to 59 Months. Indian Pediatr. 2021;58(11):1024\u20139.","journal-title":"Indian Pediatr."},{"issue":"11","key":"3286_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s13312-021-2366-4","volume":"58","author":"JI Bhat","year":"2021","unstructured":"Bhat JI, Charoo BA, Mukherjee A, Ahad R, Das RR, Goyal JP, Vyas B, Ratageri VH, Lodha R, Members of The ATU (Acute Respiratory Infection Treatment Unit) Group. Risk of hospitalization in under-five children with community-acquired pneumonia: a multicentric prospective cohort study. Indian Pediatr. 2021;58(11):1019\u201323.","journal-title":"Indian Pediatr"},{"key":"3286_CR18","unstructured":"Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/137319\/9789241507813_eng.pdf. Accessed\u00a0 4 Mar 2022"},{"key":"3286_CR19","first-page":"451","volume":"135","author":"M Christ-Crain","year":"2005","unstructured":"Christ-Crain M, M\u00fcller B. Procalcitonin in bacterial infections\u2013hype, hope, more or less? Swiss Med Wkly. 2005;135:451.","journal-title":"Swiss Med Wkly"},{"issue":"9409","key":"3286_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0140-6736(04)15591-8","volume":"363","author":"M Christ-Crain","year":"2004","unstructured":"Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600\u20137.","journal-title":"Lancet"},{"key":"3286_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2015.09.031","volume":"451","author":"B Giulia","year":"2015","unstructured":"Giulia B, Luisa A, Concetta S, Bruna LS, Chiara B, Marcello C. Procalcitonin and community-acquired pneumonia (CAP) in children. ClinicaChimica Acta. 2015;451:215\u20138.","journal-title":"ClinicaChimica Acta"},{"key":"3286_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jemermed.2017.05.035","volume":"53","author":"B Long","year":"2017","unstructured":"Long B, Long D, Koyfman A. Emergency medicine evaluation of community-acquired pneumonia: history, examination, imaging and laboratory assessment, and risk scores. J Emerg Med. 2017;53:642\u201352.","journal-title":"J Emerg Med."},{"key":"3286_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ppul.10201","volume":"35","author":"M Korppi","year":"2003","unstructured":"Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol. 2003;35:56\u201361.","journal-title":"Pediatr Pulmonol"},{"key":"3286_CR24","doi-asserted-by":"publisher","first-page":"e68419","DOI":"10.1371\/journal.pone.0068419","volume":"8","author":"G Baer","year":"2013","unstructured":"Baer G, Baumann P, Buettcher M, Heininger U, Berthet G, Schafer J, et al. Procalcitonin guidance to reduce antibiotic treatmentof lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS ONE. 2013;8:e68419.","journal-title":"PLoS ONE."},{"key":"3286_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJMoa1802670","volume":"379","author":"DT Huang","year":"2018","unstructured":"Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. ProACT Investigators. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379:236\u201349.","journal-title":"N Engl J Med."},{"key":"3286_CR26","first-page":"CD007498","volume":"10","author":"P Schuetz","year":"2017","unstructured":"Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.","journal-title":"Cochrane Database Syst Rev"},{"key":"3286_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cid\/cix317","volume":"65","author":"WH Self","year":"2017","unstructured":"Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017;65:183.","journal-title":"Clin Infect Dis"},{"key":"3286_CR28","doi-asserted-by":"publisher","first-page":"684628","DOI":"10.3389\/fped.2021.684628","volume":"9","author":"D Dudognon","year":"2021","unstructured":"Dudognon D, Levy C, Chalumeau M, Biscardi S, Dommergues MA, Dubos F, et al. Diagnostic Accuracy of Routinely Available Biomarkers to Predict Bacteremia in Children With Community-Acquired Pneumonia: A Secondary Analysis of the GPIP\/ACTIV Pneumonia Study in France, 2009\u20132018. Front Pediatr. 2021;9:684628.","journal-title":"Front Pediatr."},{"key":"3286_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00365540600951283","volume":"39","author":"M Don","year":"2007","unstructured":"Don M, Valent F, Korppi M, Falleti E, De Candia A, Fasoli L, et al. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood. Scand J Infect Dis. 2007;39:129\u201337.","journal-title":"Scand J Infect Dis."},{"issue":"Suppl 1","key":"3286_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.cegh.2015.11.005","volume":"3","author":"KK Yadav","year":"2015","unstructured":"Yadav KK, Awasthi S, Takia L, Agarwal J, Agarwal GG. Procalcitonin and C-reactive protein in WHO defined severe and very severe community acquired pneumonia: A hospital based cross-sectional study. Clin Epidemiol Global Health. 2015;3(Suppl 1):S3\u20139.","journal-title":"Clin Epidemiol Global Health."},{"key":"3286_CR31","first-page":"406","volume":"30","author":"JY Lee","year":"2010","unstructured":"Lee JY, Hwang SJ, Shim JW, Jung HL, Park MS, Woo HY, Shim JY. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia. Korean J Lab Med. 2010;30:406\u201313.","journal-title":"Korean J Lab Med"},{"key":"3286_CR32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/INF.0000000000000763","volume":"34","author":"TS Fonseca","year":"2015","unstructured":"Fonseca TS, Gendrel D, Ruuskanen O, Nascimento-Carvalho CM. Pleural Effusion Increases Serum Procalcitonin Values in Children with Community-acquired Pneumonia. Pediatr Infect Dis J. 2015;34:914\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"3286_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/INF.0b013e318170b678","volume":"27","author":"CY Chiu","year":"2008","unstructured":"Chiu CY, Wong KS, Huang JL, Tasi MH, Lin TY, Hsieh SY. Proinflammatory cytokines, fibrinolytic systemenzymes, and biochemical indices in children with infectious para-pneumonic effusions. Pediatr Infect Dis J. 2008;27:699\u2013703.","journal-title":"Pediatr Infect Dis J."}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03286-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:08:12Z","timestamp":1650539292000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03286-2","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from Ethics Committee of KIMS,Hubballi and other five study sites. Written informed consent was obtained from legal guardians\/parents of participants. A copy of consent form was given to parents\/ guardian. Personal information (paper and electronic registers) were stored in an appropriate manner so as to ensure full confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing\ninterests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}